Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
Abstract Background A treatment of HCV infection depends on the genotype and sub-genotype. Therefore, accurate HCV genotyping is critical for selecting the appropriate treatment regimen. Method This study included 280 plasma samples to evaluate the performance of 6 HCV Genotyping 9G test. The perfor...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | Virology Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12985-018-1017-4 |
id |
doaj-681b49f31f5d435b9765b9b7a06352b4 |
---|---|
record_format |
Article |
spelling |
doaj-681b49f31f5d435b9765b9b7a06352b42020-11-24T21:24:04ZengBMCVirology Journal1743-422X2018-07-011511710.1186/s12985-018-1017-4Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samplesShrikant Dasharath Warkad0Satish Balasaheb Nimse1Keum-Soo Song2Wasun Chantratita3Viroj Pongthanapisith4Laxman Uddhav Nawale5Taisun Kim6Institute for Applied Chemistry and Department of Chemistry, Hallym UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityDepartment of Pathology, Faculty of Medicine, Virology Laboratory, Ramathibodi Hospital, Mahidol UniversityDepartment of Pathology, Faculty of Medicine, Virology Laboratory, Ramathibodi Hospital, Mahidol UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityInstitute for Applied Chemistry and Department of Chemistry, Hallym UniversityAbstract Background A treatment of HCV infection depends on the genotype and sub-genotype. Therefore, accurate HCV genotyping is critical for selecting the appropriate treatment regimen. Method This study included 280 plasma samples to evaluate the performance of 6 HCV Genotyping 9G test. The performance of 6 HCV Genotyping 9G test for accurate detection of HCV 1a, 1b, 2, 3, 4, and 6 genotypes was evaluated by comparing it with LiPA 2.0 assay and sequencing. Results 6 HCV Genotyping 9G test and LiPA 2.0 assay demonstrated 83.9% (n = 235) agreement. 39/45 samples that showed discrepant results between the two tests were analyzed by sequencing. Sequencing genotyped 39 discrepant samples as 0 (HCV 1a), 24 (HCV 1b), 1 (HCV 6f), 12 (HCV 6i), and 2 (HCV-negative). Results of 6 HCV Genotyping 9G test were very similar to the sequencing as it detected 1, 23, 1, 12, and 2 samples as HCV 1a, 1b, 3 & 6a or 6f, 6i or 6n, and negative, respectively. However, LiPA 2.0 assay showed complete disagreement with sequencing, as it did not detect any of these 39 samples correctly. These results indicate that LiPA 2.0 assay has limitations in identifying HCV genotypes 1b, and 6. The sensitivity, specificity, PPV, and NPV of 6 HCV Genotyping 9G test were 99.5, 98.8, 99.5, and 98.8%, respectively. It is important to note that HCV Genotyping 9G test showed 98.3 and 100% sensitivity for HCV 1b and 6 genotyping, respectively. However, LiPA 2.0 assay demonstrated 57.9 and 71.7% sensitivity for these genotypes. Conclusions 6 HCV Genotyping 9G test identifies HCV 1a, 1b, 2, 3, and 6 with good agreement with sequencing. Hence, 6 HCV Genotyping 9G test has a high clinical value because it can provide critical information to physicians and assist them to use the correct drug for efficient hepatitis C treatment.http://link.springer.com/article/10.1186/s12985-018-1017-4HCVHCV genotyping9G DNA technologyINNO-LiPA, liver cirrhosis, hepatocellular carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shrikant Dasharath Warkad Satish Balasaheb Nimse Keum-Soo Song Wasun Chantratita Viroj Pongthanapisith Laxman Uddhav Nawale Taisun Kim |
spellingShingle |
Shrikant Dasharath Warkad Satish Balasaheb Nimse Keum-Soo Song Wasun Chantratita Viroj Pongthanapisith Laxman Uddhav Nawale Taisun Kim Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples Virology Journal HCV HCV genotyping 9G DNA technology INNO-LiPA, liver cirrhosis, hepatocellular carcinoma |
author_facet |
Shrikant Dasharath Warkad Satish Balasaheb Nimse Keum-Soo Song Wasun Chantratita Viroj Pongthanapisith Laxman Uddhav Nawale Taisun Kim |
author_sort |
Shrikant Dasharath Warkad |
title |
Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples |
title_short |
Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples |
title_full |
Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples |
title_fullStr |
Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples |
title_full_unstemmed |
Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples |
title_sort |
performance of 6 hcv genotyping 9g test for hcv genotyping in clinical samples |
publisher |
BMC |
series |
Virology Journal |
issn |
1743-422X |
publishDate |
2018-07-01 |
description |
Abstract Background A treatment of HCV infection depends on the genotype and sub-genotype. Therefore, accurate HCV genotyping is critical for selecting the appropriate treatment regimen. Method This study included 280 plasma samples to evaluate the performance of 6 HCV Genotyping 9G test. The performance of 6 HCV Genotyping 9G test for accurate detection of HCV 1a, 1b, 2, 3, 4, and 6 genotypes was evaluated by comparing it with LiPA 2.0 assay and sequencing. Results 6 HCV Genotyping 9G test and LiPA 2.0 assay demonstrated 83.9% (n = 235) agreement. 39/45 samples that showed discrepant results between the two tests were analyzed by sequencing. Sequencing genotyped 39 discrepant samples as 0 (HCV 1a), 24 (HCV 1b), 1 (HCV 6f), 12 (HCV 6i), and 2 (HCV-negative). Results of 6 HCV Genotyping 9G test were very similar to the sequencing as it detected 1, 23, 1, 12, and 2 samples as HCV 1a, 1b, 3 & 6a or 6f, 6i or 6n, and negative, respectively. However, LiPA 2.0 assay showed complete disagreement with sequencing, as it did not detect any of these 39 samples correctly. These results indicate that LiPA 2.0 assay has limitations in identifying HCV genotypes 1b, and 6. The sensitivity, specificity, PPV, and NPV of 6 HCV Genotyping 9G test were 99.5, 98.8, 99.5, and 98.8%, respectively. It is important to note that HCV Genotyping 9G test showed 98.3 and 100% sensitivity for HCV 1b and 6 genotyping, respectively. However, LiPA 2.0 assay demonstrated 57.9 and 71.7% sensitivity for these genotypes. Conclusions 6 HCV Genotyping 9G test identifies HCV 1a, 1b, 2, 3, and 6 with good agreement with sequencing. Hence, 6 HCV Genotyping 9G test has a high clinical value because it can provide critical information to physicians and assist them to use the correct drug for efficient hepatitis C treatment. |
topic |
HCV HCV genotyping 9G DNA technology INNO-LiPA, liver cirrhosis, hepatocellular carcinoma |
url |
http://link.springer.com/article/10.1186/s12985-018-1017-4 |
work_keys_str_mv |
AT shrikantdasharathwarkad performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples AT satishbalasahebnimse performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples AT keumsoosong performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples AT wasunchantratita performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples AT virojpongthanapisith performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples AT laxmanuddhavnawale performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples AT taisunkim performanceof6hcvgenotyping9gtestforhcvgenotypinginclinicalsamples |
_version_ |
1725989883958263808 |